News Sentiment

HALO sentiment intelligence

Halozyme Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 63 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 77.81 Week of 17 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+2.1% over one week, +13.5% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Is Halozyme ENHANZE Deal Reshaping Subcutaneous Antibody Delivery For Incyte’s Pipeline Strategy (INCY)?

Market Reaction

Balanced read

67/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction 2.1% Price confirming higher
Trend fit Trend active 13.5% over four weeks
Fair value 40.5% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 25
Neutral 34
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
TradingView 7
Stock Titan 7
simplywall.st 6
Quartr 5
Investing.com Canada 3
Sahm 3
Investing.com 3

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 17
Deals and strategy 7
Analyst action 4
Regulatory and legal 2
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 63
Investing.com Direct company coverage

Halozyme president & CEO Helen Torley sells $153,390 in stock

Helen Torley, President and CEO of Halozyme Therapeutics, Inc. (NASDAQ:HALO), sold 1,923 shares for $153,390 after exercising stock options. These transactions were conducted under a pre-arranged trading plan, and Torley now directly owns 767,780 shares. The company has also seen

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 22:05
Source
Investing.com
Stock Titan Direct company coverage

Halozyme (HALO) CEO sells 1,923 exercised shares under Rule 10b5-1 plan

Halozyme Therapeutics President and CEO Helen Torley exercised options for 1,923 shares at $12.07 each and immediately sold them in open-market transactions between $79 and $80 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted in Ma

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 21:05
Source
Stock Titan
AD HOC NEWS Direct company coverage

Halozyme Therapeutics focuses on drug-delivery partnerships as investors watch Nasdaq biotech sentim

Halozyme Therapeutics centers its growth strategy on developing drug-delivery collaborations with major pharmaceutical partners, focusing on turning hospital infusions into more convenient subcutaneous injections. The company generates revenue through milestones, royalties, and f

Tone
Positive 75/100
Event
Earnings
Published
08 Jul 2026 19:41
Source
AD HOC NEWS
Quartr Direct company coverage

Halozyme Therapeutics (HALO) TD Cowen 45th Annual Healthcare Conference Summary

Halozyme Therapeutics presented at the TD Cowen 45th Annual Healthcare Conference, focusing on its MHA patent portfolio for subcutaneous drug delivery, distinct from ENHANZE, and its licensing strategy, including potential litigation with Merck over Keytruda. The company highligh

Tone
Positive 70/100
Event
Market update
Published
08 Jul 2026 16:39
Source
Quartr
Investing.com Direct company coverage

Halozyme signs collaboration deal with GSK for oncology targets

Halozyme Therapeutics has entered into a global collaboration and license agreement with GSK to develop subcutaneous formulations of multiple oncology targets, including antibody drug conjugates, using Halozyme's ENHANZE drug delivery technology. The deal involves an upfront paym

Tone
Positive 73/100
Event
Deals and strategy
Published
05 Jul 2026 15:11
Source
Investing.com
Investing.com Direct company coverage

Halozyme licenses Hypercon technology to Vertex for $15M

Halozyme Therapeutics announced a global collaboration and license agreement with Vertex Pharmaceuticals, granting Vertex access to Halozyme's Hypercon technology for up to three drug targets in exchange for a $15 million upfront payment. Halozyme is also eligible for future mile

Tone
Positive 74/100
Event
Market update
Published
05 Jul 2026 03:40
Source
Investing.com